Semax (ACTH Fragment Peptide)

Semax in the Published Literature

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

PubMed indexes roughly 231 Semax records. The mechanistic literature appears in international journals including Brain Research and BMC Genomics and is conducted almost entirely in rats. The clinical literature is concentrated in Russian-language journals, principally the Korsakov Journal of Neurology and Psychiatry.

Key facts

Indexed PubMed records
~231
Mechanistic work
Predominantly rat models
International journals
Brain Res, BMC Genomics, J Mol Neurosci
Clinical work
Largely Russian-language
Principal clinical journal
Zh Nevrol Psikhiatr Im S S Korsakova
Earliest clinical records
Late 1990s
Western regulatory review
None

Two literatures, not one

Semax's evidence base splits unusually cleanly. Mechanistic and preclinical work appears in international peer-reviewed journals and is accessible in English: the BDNF and trkB study in Brain Research, the focal-ischaemia transcriptomics in BMC Genomics, the neurotrophin dynamics work in the Journal of Molecular Neuroscience. Clinical work is concentrated in Russian-language publications, indexed on PubMed by title translation but frequently without accessible English full text.

What that means for assessment

It creates an asymmetry. A reader can evaluate the preclinical mechanistic claims directly, because the papers are available and the methods are described in a language and format they can check. The clinical claims are harder to assess independently. That is not because the work does not exist, but because language and access barriers sit between the reader and the methods. Neither dismissing it nor accepting it uncritically is defensible.

Research material referenced

Semax 10mg, third-party HPLC tested

Buy Semax · £24.99

Age of the clinical record

Records on Semax in ischaemic stroke appear from the late 1990s, with further work published subsequently. Trials from that period generally predate current standards for pre-registration, estimand specification and reporting. That is a statement about when the work was done rather than a judgement of the investigators.

Scale, in context

231 records is a modest literature. For comparison, BPC-157 and TB-500 have accumulated comparable or larger bodies of work, while a widely used approved medicine typically has thousands. Around a decade of concentrated attention plus a longer tail of Russian institutional research produces a body of evidence that is real but not deep.

How to search it

PubMed indexes the field under 'Semax'. Filtering to English-language records isolates the internationally published mechanistic work; removing that filter reveals how much of the clinical record sits outside it. Comparing the two counts is itself informative about the shape of the evidence.

Frequently asked questions

Is the Russian clinical literature legitimate?

It is peer-reviewed and PubMed-indexed. The difficulty is access and independent assessment, not existence. Treat it as evidence that is hard to verify rather than as evidence that is absent.

Are there Western clinical trials of Semax?

No substantial Western clinical programme exists, and no Western regulator has reviewed it.

Which paper is the best starting point?

The 2006 Brain Research study on BDNF and trkB expression, PMID 16996037, is the most cited mechanistic entry point.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Semax (ACTH Fragment Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.